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Abstract
Background: Where health economic studies are frequently performed using modelling, with input from
randomized controlled trials and best guesses, we used real-life data to analyse the cost-effectiveness and cost-
utility of a treatment strategy aiming to the target of remission compared to usual care in early rheumatoid arthritis
(RA).
Methods: We used real-life data from comparable cohorts in the Dutch Rheumatoid Arthritis Monitoring (DREAM)
registry: the DREAM remission induction cohort (treat-to-target, T2T) and the Nijmegen early RA inception cohort
(usual care, UC). Both cohorts were followed prospectively using the DREAM registry methodology. All patients
fulfilled the American College of Rheumatology criteria for RA and were included in the cohort at the time of
diagnosis. The T2T cohort was treated according to a protocolised strategy aiming at remission (Disease Activity
Score in 28 joints (DAS28) < 2.6). The UC cohort was treated without DAS28-guided treatment decisions.
EuroQol-5D utility scores were estimated from the Health Assessment Questionnaire. A health care perspective
was adopted and direct medical costs were collected. The incremental cost effectiveness ratio (ICER) per patient in
remission and incremental cost utility ratio (ICUR) per quality-adjusted life year (QALY) gained were calculated over
two and three years of follow-up.
Results: Two year data were available for 261 T2T patients and 213 UC patients; an extended follow-up of three
years was available for 127 and 180 patients, respectively. T2T produced higher remission percentages and a larger
gain in QALYs than UC. The ICER was € 3,591 per patient in remission after two years and T2T was dominant after
three years. The ICUR was € 19,410 per QALY after two years and T2T was dominant after three years.
Conclusions: We can conclude that treating to the target of remission in early RA is cost-effective compared with
UC. The data suggest that in the third year, T2T becomes cost-saving.
Background
Treating to the target of remission has become the new
paradigm for the treatment of patients with rheumatoid
arthritis (RA) [1]. The key elements of treat-to-target
(T2T) are: monitoring disease activity, subsequently
adjusting medication in accordance to a fixed protocol,
and aiming at a predefined target. In clinical trials it has
been demonstrated that a T2T approach is more effective
in lowering disease activity and, ultimately, reaching re-
mission than usual care [2-7].
Taking into account that treating RA comes with po-
tential high costs, it is mandatory to study the balance
between costs and effects and ultimately gained quality
of life. Health economic studies addressing this question
frequently use modelling as methodology to evaluate this
balance. These studies use data from pivotal trials and
best guesses by opinion leaders to feed the model. For
prediction before or early after introducing innovations
to the market, modelling is a realistic approach. How-
ever, clinical trial data, clinical experience and mathem-
atical models have their restrictions. Therefore, real-life
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data are needed to study the economic impact of inno-
vations in health care compared with usual care.
In the Dutch Rheumatoid Arthritis Monitoring
(DREAM) registry, 11 centres prospectively acquire
standardized data on their RA patients. In the DREAM
registry, centres participate in different levels and co-
horts. One of the DREAM cohorts is the DREAM re-
mission induction cohort. With this cohort we have
demonstrated that a T2T strategy aiming for remission
(Disease Activity Score in 28 joints (DAS28) < 2.6 [8]) is
very effective in daily clinical practice, with percentages
of DAS28 remission ranging from 47% after six months
to 58% after twelve months [9]. In this early RA cohort,
remission was achieved rapidly with a median time to
first remission of 25 weeks. Moreover, this T2T strategy
resulted in beneficial clinical outcomes after one year
compared to usual care treatment [7].
Early and effective suppression of disease activity is
expected to reduce pain, prevent progression of joint dam-
age and disability [10,11], and increase the patient’s quality
of life [12,13]. The concept of T2T assumes that intensive
efforts and costs are made in the beginning of the disease
to gain health and cost savings later. However, the question
is whether indeed the health benefits outweigh the extra
costs associated with performing a T2T approach.
The objective of this health economic study is to evalu-
ate the cost-effectiveness and cost-utility, from a health
care perspective, of a T2T strategy aiming at remission
compared to usual care for the treatment of early RA pa-
tients in real-life daily clinical practice over a period of up
to three years.
Methods
Study design
The data in this study are prospectively acquired in par-
ticipating centres of the DREAM registry. Post-hoc we
analysed the data of two cohorts. All DREAM centres
are stationed in the eastern part of The Netherlands and
have the same health care and reimbursement system.
The T2T cohort consisted of patients from the DREAM
remission induction cohort and the usual care (UC) co-
hort consisted of patients from the Nijmegen early RA
inception cohort [14]. This study can be defined as a
quasi-experiment because unselected patients were in-
cluded in both cohorts with ‘living area’ as main deter-
minant for being included in either one of the cohorts.
In both cohorts, all clinical data on patient characteris-
tics, medication, clinical and laboratory measures were
assessed in a standardized way and stored prospectively
in electronic databases. Currently, in both cohorts, new
patients are still being included and follow-up continues.
The local medical ethics committees have approved the
prospective data acquisition of both inception cohorts
(Medisch Spectrum Twente Hospital for the T2T cohort
and CMO region Arnhem-Nijmegen for the usual care
cohort). Each patient gave informed consent before the
inclusion in the cohorts.
DREAM registry - treat-to-target
Since January 2006, patients were enrolled in the DREAM
remission induction cohort [9]. A T2T strategy including
standardised and protocolised treatment adjustments aim-
ing at remission (DAS28 < 2.6) was applied. Patients vis-
ited the clinic at weeks 0, 8, 12, 20, 24, 36 and 52, and
every three months thereafter. Therapy consisted of
initial methotrexate monotherapy (MTX), followed by
the addition of sulfasalazine (SSZ), and thereafter in the
case of persistent disease activity, sulfasalazine was
replaced with anti-tumour necrosis factor (TNF) α
agents. If the target of DAS28 < 2.6 was met, medication
was not changed. In case of sustained remission (≥ six
months), medication was gradually reduced and eventu-
ally discontinued. Nonsteroidal anti-inflammatory drugs
(NSAIDs), prednisolone at a dosage of ≤ 10 mg/day, and
intra-articular corticosteroid injections were allowed at
the discretion of the attending rheumatologist. Data col-
lection, including assessment of the DAS28, was per-
formed by trained rheumatology nurses.
DREAM registry - usual care
Follow-up and data acquisition for the usual care cohort
were similar to the T2T cohort in the DREAM registry.
Every three months, the DAS28 was assessed by trained
rheumatology nurses. In contrast to a T2T approach, the
DAS28 values were not generally provided to the treating
rheumatologist and pharmacological treatment was not
protocolised but at the discretion of the rheumatologist. In
general, patients were treated with step-up or sequential
monotherapy with conventional disease-modifying anti-
rheumatic drugs (DMARDs) and/or biologic, notably anti-
TNF. Prednisolone (oral or injections) and NSAIDs could
also be used. The most commonly applied strategy was
starting with MTX monotherapy, subsequently switching
to SSZ or adding SSZ in case of MTX failure, and adding
an anti-TNF agent after two or more DMARDs had failed.
Selection of patients
For the current study, we selected patients from both
cohorts who fulfilled the following inclusion criterion:
RA according to the American College of Rheumatology
1987 classification criteria for RA [15], age ≥ 18 years,
symptom duration of less than one year, and no previous
treatment with DMARDs. Patients diagnosed between
January 2000 and February 2009 with a minimal follow-
up of two years were selected. The DREAM remission
induction cohort started in 2006. Although we hoped to
have sufficient data on UC in a comparable time slot, we
had to include patients for the UC group diagnosed
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from January 2000 onwards in order to obtain a suffi-
cient number of patients. We chose 2000 as a minimum
year of inclusion because since then biologic agents, es-
pecially TNF blockers, were already available and reim-
bursed with restriction in daily practice.
Patients from the T2T cohort visited Arthritis Center
Twente at Medisch Spectrum Twente, Enschede and the
departments of rheumatology from Ziekenhuisgroep
Twente, Almelo/Hengelo and Isala Klinieken, Zwolle. Pa-
tients from the UC cohort visited the Radboud University
Nijmegen Medical Centre or Maartenskliniek, Nijmegen.
Measurements
The effectiveness of treatment was evaluated using the
DAS28 (calculated using the erythrocyte sedimentation
rate (ESR)). A DAS28 < 2.6 was defined as remission [16].
Utilities were estimated to evaluate the effect of treat-
ment on health-related quality of life. Utility is the valu-
ation of a health state on a scale of 0 (equivalent to
death) to 1 (equivalent to full health) and is used to derive
quality-adjusted life years (QALYs) [17]. Because prefer-
ence based measures were not prospectively assessed,
EuroQol-5D (EQ-5D) values [18] were estimated from the
Health Assessment Questionnaire (HAQ) scores [19,20]
by using model 5 of the mapping method by Bansback
et al. [21]. This model was reported to be the most suc-
cessful of the five mapping methods, by having the lowest
mean square error and the best predictive value [21,22].
Concordantly, the QALYs were computed according to
the trapezium rule.
Cost analysis
The cost analysis exists of two main parts. First, on patient
level, volumes of care related to the T2T strategy or usual
care were determined. Volumes of hospital related care, i.e.
consultations with the rheumatologist and the rheumatol-
ogy nurse, telephonic consultations (rheumatologist), and
hospital admissions related to RA, were retrieved from the
hospital information system. Medication use (exact dose
of medication and administration period) was prospect-
ively registered in the electronic case report forms.
The second part of the cost analysis consisted of deter-
mining the cost prices for each volume of consumption.
Volumes of care were multiplied by the cost prices for
each volume of care to calculate costs. The standard cost
prices from the Dutch Guideline for Cost Analyses were
used for hospital related care (see Appendix) [23]. The
price based on personnel, material and overhead of day
care hospital admissions required for treatment with
infliximab or rituximab was estimated at a mean of €
122 per day (on top of the medication costs). Cost prices
for medication were retrieved from the Dutch national
tariff list provided by the Dutch Board of Health Insur-
ances [23].
The base year was 2011 for all prices. Prices retrieved
from other years were converted to 2011 euros using the
general Dutch price index rate [24].
Statistical analysis
Data of two year follow-up were analysed as well as an
extended follow-up of three years in patients who had
sufficient follow-up. Our expectation was that on the
long-term, costs associated with performing T2T will de-
crease. In our previous study, the necessary sample size
to detect a difference in remission of 20% between both
groups was estimated to be at least 2×125 = 250 patients
[7]. This sample size estimation was satisfied in the two
and three years data analyses in the present study.
The incremental cost-effectiveness ratio (ICER) was
calculated by dividing the difference in costs by the dif-
ference in effectiveness (based on the number of patients
in remission) derived from the two groups. The ICER is
expressed as costs per one more patient in remission.
The incremental cost-utility ratio (ICUR) was calculated
by dividing the difference in costs by the difference in
the QALYs produced by the two groups. The ICUR is
expressed as costs per QALY gained. Uncertainty in both
ratios was determined non-parametrically using boot-
strap techniques. Results of the 1,000 bootstrapped repli-
cations are presented in cost-effectiveness planes that
graphically present the uncertainty around the ratio of
the two and three years data. In a sub-analysis, the ratios
were calculated for patients that were included in the
cohorts from 2006. However, statistical power was ex-
pected to be low due to the low number of UC patients.
Missing values were imputed with single imputation
using a regression method including a random component
for the ESR, patient’s assessment of general health, and
HAQ question 23 (take a tub bath) or linear interpolation
using the trapezoid method for the DAS28 and EQ-5D
scores, conditional on the data being missing at random.
The level of significance was set at a p value < 0.05. Stat-
istical analyses were performed using the statistical soft-
ware package SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
The bootstrap was performed in Excel.
Results
Baseline characteristics
Two year follow-up data were available for 261 patients
of the T2T cohort and for 213 patients of the UC cohort.
An extended three years follow-up was available for a
smaller proportion of patients due to insufficient follow-
up; i.e. in 127 of the 261 (48.7%) T2T patients and 180
of the 213 (84.5%) UC patients. Baseline characteristics
were comparable between patients with and without suf-
ficient follow-up.
Table 1 presents the demographic and clinical charac-
teristics of both groups at baseline. The groups were
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comparable at baseline regarding age, gender, rheuma-
toid factor (RF) positivity, number of tender joints (28
assessed) and ESR. Statistically significant but small dif-
ferences were found for the mean DAS28, number of
swollen joints (28 assessed), C-reactive protein, patient’s
assessment of general health and pain, and HAQ score,
which were higher in the T2T group.
MTX monotherapy was the initial treatment in the
T2T group by protocol. In the UC group, patients started
with SSZ monotherapy (45.5%, 97/213), MTX monother-
apy (43.7%, 93/213) or occasionally another DMARD
(6.6%, 14/213) or no medication (4.2%, 9/213).
Health outcomes
Table 2 presents the health outcome results after two
and three years of follow-up. After two years, 64.4%
(168/261) of the T2T group was in remission versus
34.7% (74/213) of the UC group (p < 0.001). Over the
first two years of treatment, the median (interquartile
range, IQR) of QALYs was higher in the T2T group than
in the UC group (1.45 (1.24-1.55) versus 1.39 (1.18-
1.53), respectively, p = 0.04).
After three years, the remission percentages were
59.8% (76/127) with T2T versus 35.0% (63/180) with UC
(p < 0.001). The median (IQR) of QALYs over the first
three years was higher in the T2T group than in the UC
group (2.19 (1.81-2.34) versus 2.04 (1.64-2.27), respect-
ively, p = 0.05).
Care consumption and costs
Table 3 presents the amount of care consumption and
mean costs per patient during two and three years of
follow-up. Over both periods, the numbers of consulta-
tions with the rheumatologist were comparable, whereas
Table 1 Baseline characteristics of the patients of the treat-to-target (T2T) and usual care (UC) groups
T2T (n=261) UC (n=213) UC from 2006 (n=69)
Age, mean ± SD years 57.9 ± 13.8 56.6 ±13.4 53.9 ±13.0†
Female sex, n (%) 161 (61.7) 132 (62.0) 43 (62.3)
RF positive, n (%) 178 (68.2) 147/211 (69.7) 48/69 (69.6)
DAS28, mean ± SD 5.0 ± 1.1 4.8 ± 1.2† 4.8 ± 1.3
No. of swollen joints (28 assessed), median (IQR) 8 (5–12) 9 (6–13)† 8 (5–12)
No. of tender joints (28 assessed), median (IQR) 5 (2–9) 4 (2–9) 4 (1–9)
ESR, median (IQR) mm/hour 28.0 (15.5-42.0) 26.0 (12.0-39.0) 29.0 (17.0-43.5)
CRP, median (IQR) mg/litre 14.0 (5.0-34.5) 6.7 (0.0-27.8)† 10.0 (0.0-34.3)
VAS general health, mean ± SD (0–100) 52.9 ± 22.6 45.7 ± 23.0† 42.9 ± 24.4†
VAS pain, mean ± SD (0–100) 51.2 ± 21.9 44.9 ± 23.2† 46.5 ± 23.9
HAQ score, median (IQR) 1.1 (0.6-1.5) (n=244) 0.9 (0.5-1.4) (n=151)† 0.9 (0.4-1.4) (n=52)†
CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile
range; RF, rheumatoid factor; SD, standard deviation; VAS, visual analog scale.
† P < 0.05 for differences between groups (T2T versus UC).
Table 2 Health outcomes in the treat-to-target (T2T) and usual care (UC) groups after two and three years of follow-up
Two years Three years
T2T (n=261) UC (n=213) UC from 2006
(n=69)
T2T (n=127) UC (n=180) UC from 2006
(n=45)
DAS28, mean ± SD 2.4 ± 1.0 3.1 ± 1.3† 2.8 ± 1.1† 2.5 ± 1.0 3.1 ± 1.3† 2.7 ± 1.1
DAS28 level, n (%)
Remission
(DAS28 < 2.6)
168 (64.4) 74 (34.7)† 33 (47.8)† 76 (59.8) 63 (35.0)† 25 (55.6)
Low
(2.6 ≤ DAS28 ≤ 3.2)
48 (18.4) 44 (20.7) 14 (20.3) 28 (22.0) 35 (19.4) 5 (11.1)
Moderate
(3.2 < DAS28 ≤ 5.1)
37 (14.2) 76 (35.7)† 19 (27.5)† 21 (16.5) 72 (40.0)† 14 (31.1)†
High (DAS28 > 5.1) 8 (3.1) 19 (8.9)† 3 (4.3) 2 (1.6) 10 (5.6) 1 (2.2)
QALYs, median (IQR) 1.45 (1.24-1.55)
(n=221)
1.39 (1.18-1.53)
(n=143)†
1.44 (1.21-1.55)
(n=47)
2.19 (1.81-2.34)
(n=101)
2.04 (1.64-2.27)
(n=106)†
1.95 (1.50-2.34)
(n=18)
Quality-adjusted life years (QALYs) were derived from the EuroQol-5D utility scores which were estimated from the Health Assessment Questionnaire (HAQ).
QALYs could not be evaluated in all patients due to missing data in (items of) the HAQ.
DAS28, Disease Activity Score in 28 joints; SD, standard deviation.
† P < 0.05 for differences between groups (T2T versus UC).
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the numbers of consultations with the rheumatology
nurse and telephonic consultations were higher in the
T2T group. In usual care, more hospital admissions were
observed than with T2T.
Over the first two years, the mean (standard deviation,
SD) total direct costs per patient were € 4,791 (7,436) in
the T2T group and € 3,727 (5,773) in the usual care
group (Table 3). The observed difference in costs be-
tween groups was mainly generated by the costs of anti-
TNF therapy and hospitalization. During the first two
years of treatment, 21.5% (56/261) of the T2T group re-
ceived anti-TNF therapy versus 15.0% (32/213) of the
UC group.
Over the first three years, the mean (SD) total direct
costs per patient were € 6,410 (10,845) in the T2T group
and € 6,872 (11,033) in the UC group (Table 3). The ob-
served difference in costs between groups was mainly
generated by hospitalization.
Overall, the mean (SD) time until the first anti-TNF
agent was started was shorter in the T2T group com-
pared to the UC group (mean (SD) of 58 (29) weeks ver-
sus 80 (39) weeks, respectively, p = 0.002).
Cost-effectiveness
After two years of follow-up, the ICER was € 3,591 per
patient in remission and after three years of follow-up
Table 3 Mean volumes of care and total direct costs in euros per patient per period in the treat-to-target (T2T) and
usual care (UC) groups after two and three years of follow-up
0-2 year
T2T (n=261) UC (n=213) UC from 2006 (n=69)
Volume Costs Volume Costs Difference
in costs
Volume Costs Difference
in costs
Consultations
rheumatologist
10.4 ± 3.0 696 ± 199 10.3 ± 2.9 689 ± 195 7 10.2 ± 3.6 683 ± 239 13
Consultations
nurse
8.8 ± 3.0 588 ± 200 7.8 ± 1.9† 522 ± 127† 66 6.6 ± 2.0† 438 ± 134† 150
Telephonic
consultations
1.3 ± 1.8 34 ± 46 0.6 ± 1.4† 16 ± 36† 18 1.1 ± 1.9 29 ± 48 5
Hospital
admissions
0.4 ± 2.7 178 ± 1,208 1.1 ± 4.2† 521 ± 1,901† −343 0.3 ± 1.6 158 ± 714 20
Medication
DMARDs/other 174 ± 165 249 ± 340 −75 166 ± 119 8
Anti-TNF 3,121 ± 7,162 1,730 ± 4,905† 1,391 1,877 ± 5,086 1244
Total 4,791 ± 7,436 3,727 ± 5,773 1,064
(1,026 to 1,121)‡
3,351 ± 5,179† 1440
(1,387 to 1479)‡
0-3 year
T2T (n=127) UC (n=180) UC from 2006 (n=45)
Volume Costs Volume Costs Difference
in costs
Volume Costs Difference
in costs
Consultations
rheumatologist
13.7 ± 3.3 917 ± 220 13.6 ± 3.3 909 ± 224 8 12.5 ± 3.8 838 ± 253† 79
Consultations
nurse
12.1 ± 3.6 809 ± 244 8.9 ± 1.7† 596 ± 117† 213 8.4 ± 2.2† 565 ± 145† 244
Telephonic
consultations
1.9 ± 2.1 49 ± 54 0.8 ± 1.7† 21 ± 45† 28 1.7 ± 2.5 43 ± 64 6
Hospital
admissions
0.5 ± 3.2 215 ± 1,441 1.6 ± 5.0† 748 ± 2,263† −533 0.8 ± 2.7 364 ± 1,217 −149
Medication
DMARDs/other 260 ± 335 423 ± 612† −163 259 ± 174 1
Anti-TNF 4,160 ± 10,685 4,175 ± 10,070 −15 5,488 ± 11,528 −1,328
Total 6,410 ± 10,845 6,872 ± 11,033 −462
(−513 to −350)‡
7,558 ± 11,649 −1,148
(−1241 to −1075)‡
Volumes are the mean ± standard deviation (SD).
Anti-TNF, anti-tumour necrosis factor; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs.
† P < 0.05 for differences between groups (T2T versus UC). ‡ 95% confidence interval bootstrapped.
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the T2T strategy was dominant. Figure 1 presents the
cost-effectiveness planes, showing the relation between
the difference in effect (x-axis) and the difference in costs
(y-axis) between T2T and UC. Figure 1A presents the two
years data and shows that 91% of the bootstrapped ratios
were situated in the upper-right quadrant, which signifies
a gain in effectiveness against higher costs. Figure 1B
shows that after three years, 64% of the bootstrapped ra-
tios were situated in the lower-right quadrant, which
signifies lower costs and higher effectiveness.
Cost-utility
Over a period of two years, the ICUR was € 19,410 per
QALY and after three years of treatment the T2T strategy
was dominant. Figure 2 presents the cost-utility planes,
showing the relation between the difference in QALYs (x-
axis) and the difference in costs (y-axis) between T2T and
UC. Figure 2A shows that after 94% of the two years’
bootstrapped ratios were situated in the upper-right quad-
rant. Figure 2B shows that 66% of the three years’ boot-
strapped ratios were situated in the lower-right quadrant,
which signifies lower costs and higher effectiveness.
Sub-analysis
A sub-analysis was performed on patients that were
included in the cohorts from 2006. Table 1 presents
the baseline characteristics of the 69 UC patients that
were included in the UC cohort from 2006. The
Figure 1 Cost-effectiveness planes of 1000 bootstrap replicates of the incremental cost and effectiveness (based on the number of
patients in remission, defined as a Disease Activity Score in 28 joints < 2.6) of the treat-to-target strategy versus usual care in early
rheumatoid arthritis after A) two years and B) three years of follow-up.
Vermeer et al. BMC Musculoskeletal Disorders 2013, 14:350 Page 6 of 9
http://www.biomedcentral.com/1471-2474/14/350
health outcomes of these patients are presented in
Table 2 and the amount of care consumption and
mean costs per patient during two and three years of
follow-up are presented in Table 3. After two years of
follow-up, the ICER was € 8,709 per patient in remis-
sion. After three years T2T was dominant (this ana-
lysis included 45 UC patients). We were not able to
perform analysis on the ICURs because of the low
number of patients with data with on QALYs in the
UC group.
Discussion
Our study suggests that treating to the target of remis-
sion is the preferred strategy over usual care in early RA.
After two years of treatment, T2T is cost-effective as it
comes with higher costs but also with substantially higher
effectiveness. In the T2T group DAS28 remission had
been achieved more frequently and there was a larger gain
in health-related QALYs compared with UC. The ICUR
lies far below the threshold of €80,000 per QALY, which is
considered to be an acceptable willingness to pay for one
QALY in The Netherlands [25]. Moreover, the costs to
bring one more patient in remission also seem to be ac-
ceptable. Results of an extended follow-up analysis of
three year data were clearly in favor of T2T, with 64%
chance of the T2T strategy coming at lower costs with
higher effectiveness compared to UC. To our knowledge,
this is the first health economic evaluation of comparing
T2T with UC using real-life data.
The drivers of absolute costs and cost differences
between T2T and UC were anti-TNF therapy and
hospitalization. Our previous studies demonstrated that
Figure 2 Cost-utility planes of 1000 bootstrap replicates of the incremental cost and quality-adjusted life years gained by the treat-to-
target strategy versus usual care in early rheumatoid arthritis after A) two and B) three years of follow-up.
Vermeer et al. BMC Musculoskeletal Disorders 2013, 14:350 Page 7 of 9
http://www.biomedcentral.com/1471-2474/14/350
the majority of the T2T patients achieved remission
with conventional DMARDs [7,9]. According to the
treatment protocol, anti-TNF was prescribed only for a
minority of patients whose disease activity remained
moderate to high after insufficient effect of conventional
DMARDs, thereby preventing overtreatment with anti-
TNF agents with their costs and side effects. In the UC
group, anti-TNF was initiated later in the disease course,
and, therefore, it might be less effective and longer re-
quired in patients. Costs due to hospitalization were
directly related to RA. The higher number of hospital ad-
missions in the UC group might be explained by less
efficient disease control. Data on intra-articular injections
were not available. However, we do not think this can ex-
plain the difference in costs between T2T and UC, be-
cause of the low costs of injections.
The principle of T2T is to aim at achieving and sus-
taining remission as early as possible. Our expectation is
that the extra effort and time spent in the first years of
the disease, ultimately result in a reduction of the num-
ber of consultations later in the disease course and the
possibility of tapering and discontinuing medication in
case of sustained remission, thereby diminishing costs.
Therefore, we expect that on the long-term, cost savings
associated with T2T will increase. Furthermore, better
and earlier disease control might lead to more work par-
ticipation on the long-term, which will ultimately lower
the costs of T2T for society and improve quality of life
for the patients.
An important strength of this study is the quasi-
experimental design containing real-life observational
data regarding effectiveness, health-related quality of life
and costs of T2T compared with usual care. Moreover,
in the DREAM registry all consecutive patients are pro-
spectively followed and a standardized data set is col-
lected. This is in contrast to many health economic
evaluations, which often use modeling techniques with
many underlying assumptions or use clinical trial data of
highly selected patients.
However, this study has some limitations also. Obviously,
since our patients are unselected, randomisation between
the comparing cohorts was not performed with the risk of
confounding by indication present in the comparison.
However, participation in either one of the cohorts was de-
termined by living area while patients attended comparable
rheumatology clinics, all participating in the DREAM regis-
try and working within the same health care system. We as-
sume that this has limited the possibility of confounding by
indication. Furthermore, no relevant differences in baseline
characteristics which are prognostic for the treatment effect
were found. Second, it should be noted that UC patients
were included from 2000 until present, whereas T2T pa-
tients were included from 2006 until present. Even though
the same treatment options for both groups were available
during observation and anti-TNF guidelines have not been
changed since 2000, one can assume that UC has changed
between 2000 and 2006. A sub-analysis omitting UC pa-
tients recruited prior to 2006 showed comparable ICERs,
however with less statistical power, leading to the same
conclusions. Therefore, this study provides the best possible
comparison currently available. A third limitation is that a
preference based health-related quality of life measure was
not available in the UC cohort, and, therefore, we estimated
utilities from the HAQ. The HAQ has been shown to be
highly correlated with health state utility values, which are
used to calculate QALYs [26]. Nevertheless, HAQ-derived
utilities will only capture change in quality of life generated
by the patient’s functional status and not by other factors.
We expect that T2T patients improve at more dimensions
of quality of life than only function status. Therefore, we
believe that this was a conservative analysis. We acknow-
ledge that the use of a mapping method will always be sub-
optimal to primary collection of utility data. Fourth, we
applied a health care perspective, thereby taking into ac-
count only direct medical costs. However, the economic
burden of RA goes beyond health care costs [27-29] and a
societal perspective would be preferable. RA leads to sub-
stantial losses in terms of work productivity which increases
with disease duration [30,31]. Unfortunately, data on work
participation were not available. According to our view, we
performed a conservative cost analysis and our expectations
are that T2T, which decreases disease activity rapidly and
early in the disease course, will have an additional positive
effect on non-medical costs (e.g. work productivity, infor-
mal care, and paid housekeeping).
Conclusions
We performed a health economic study of T2T versus
UC, using observational data of the DREAM registry.
We conclude that treating to the target of remission in
early RA is cost-effective as compared with usual care at
the discretion of the attending physician.
Appendix
Cost prices 2011
Consult at rheumatologist (13 minutes) € 66.90
Consult at rheumatology nurse (20 minutes) € 66.90
Telephonic consult at rheumatologist (5 minutes) € 25.73
Hospital day care related to biologics € 122.13
Hospital admission (one day) € 454.69
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